ICP
CRL icon

Impact Capital Partners’s Charles River Laboratories CRL Stock Holding History

Impact Capital Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,567
Closed -$386K – 266
2025
Q1 		$386K Buy
2,567
+280
+12% +$46.9K 0.14% 166
2024
Q4 		$422K Buy
+2,287
New +$441K 0.15% 160

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Impact Capital Partners's CRL Position: Q2 2025 in Review

Impact Capital Partners sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 2,567 shares — an estimated $386K sold.

Impact Capital Partners first reported a position in CRL in Q4 2024 and held it in 2 quarters. The position peaked at $422K in Q4 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Impact Capital Partners reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Impact Capital Partners sold 2,567 Charles River Laboratories shares in Q2 2025, an estimated $386K.
  • Impact Capital Partners first reported a position in Charles River Laboratories in Q4 2024 and held it in 2 quarters.
  • Impact Capital Partners's Charles River Laboratories position peaked at $422K in Q4 2024.
  • 519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Impact Capital Partners's 13F filing for Q2 2025, filed 18 Jul 2025.